News

Innovation, adaptability, and clear communication are key to managing outcomes.

Revisiting a classic tool that still gets you out of a jam works best when you understand its powers and limitations.

Answering all the questions ophthalmologists may have ahead of the EURETINA Congress in Paris, France

Retina specialists will celebrate the major anniversary this September in Paris, France.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

In episode 1, Bill Trattler, MD, shares practical advice on documentation, patient communication, keratoconus management, and advanced lens technology.

Kriya is developing gene therapies targeting chronic diseases such as geographic atrophy, trigeminal neuralgia, and type 1 diabetes.

Catch up on this week's highlights in retina.

Opioids like fentanyl effectively prevent sneezing during propofol sedation for periocular injections, enhancing patient safety in ophthalmic procedures.

Research reveals a significant link between androgen exposure and central serous chorioretinopathy, aiding clinicians in assessing patient risk factors effectively.

Research reveals that GLP-1 medications, including semaglutide, do not increase diabetic retinopathy risks, offering reassurance for patients and prescribers.

Understand the anatomical risks, technique-specific benefits, and patient selection criteria

New support offers a streamlined experience for surgeons and patients

The clinical support system integrates artificial intelligence into OCT interpretation workflow

Alcon showcases new data at APACRS 2025, emphasizing advancements in IOL technology and surgical precision for improved patient outcomes.

Advanz Pharma and Alvotech announced AVT06, a biosimilar to Eylea, was approved for neovascular age-related macular degeneration

NCX 470 met the primary endpoint of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care, latanoprost 0.005%.

Included is the supplemental Biologics License Application (sBLA) for EYLEA HD seeking approval for both the treatment of macular edema following retinal vein occlusion (RVO) and the broadening of the dosing schedule to include every 4-week dosing across approved indications.

Research reveals how neighborhood social factors impact patients with tractional retinal detachments, highlighting the need for improved access to care and support.

Reliable visualization tools, especially those indicated for ocular use, are crucial for success.